2. Search Result
Search Result
Results for "

Thrombopoietin+Receptor

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Recombinant Proteins

2

Isotope-Labeled Compounds

4

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15306
    Eltrombopag
    Maximum Cited Publications
    24 Publications Verification

    SB-497115

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag
  • HY-15306A
    Eltrombopag Olamine
    Maximum Cited Publications
    24 Publications Verification

    Eltrombopag diethanolamine salt; SB-497115GR

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine
  • HY-122620
    Rafutrombopag (tautomerism)

    Hetrombopag (tautomerism); SHR-8735 (tautomerism)

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology
    Rafutrombopag (tautomerism) (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR‐expressing cells, including 32D‐ MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag (tautomerism)
  • HY-13463A
    Avatrombopag maleate
    5 Publications Verification

    AKR-501 maleate; E5501 maleate; YM477 maleate

    		 Thrombopoietin Receptor Cytochrome P450 ERK STAT Inflammation/Immunology Cancer
    Avatrombopag (AKR-501) maleate is an orally active, non-peptide thrombopoietin receptor (TPO receptor) agonist (EC50: 3.3 nM). Avatrombopag maleate mimics the biological activity of TPO. Avatrombopag maleate increases platelet production by activating intracellular signaling systems and promotes the production of platelets and megakaryocytes from hematopoietic precursor cells. Avatrombopag maleate is a substrate for cytochrome P450 (CYP) 2C9 and CYP3A .
    Avatrombopag maleate
  • HY-145589
    Rafutrombopag

    Hetrombopag; SHR-8735

    		 Thrombopoietin Receptor STAT PI3K ERK Apoptosis CDK Cardiovascular Disease Inflammation/Immunology Cancer
    Rafutrombopag (Hetrombopag) is an orally active nonpeptide thrombopoietin receptor (TPOR/MPL) agonist. Rafutrombopag can chelate iron and alleviate iron overload while promoting haematopoiesis. Rafutrombopag specifically stimulates proliferation and differentiation of human TPOR-expressing cells, including 32D-MPL and human hematopoietic stem cells through stimulation of STAT, PI3K and ERK signalling pathways. Rafutrombopag effectively up-regulates G1-phase-related proteins, including p-RB, Cyclin D1 and CDK4/6, normalizes progression of the cell cycle, and prevents apoptosis by modulating BCL-XL/BAK expression in 32D-MPL cells. Rafutrombopag protects cardiomyocyte survival from oxidative stress damage as an enhancer of stem cells. Rafutrombopag can be used for the study of immune thrombocytopenia and oxidative stress-related cardiovascular disease .
    Rafutrombopag
  • HY-15306S
    Eltrombopag-13C4
    1 Publications Verification

    SB-497115-13C4

    		 Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag- 13C4 (SB-497115- 13C4) is 13 sup>C-labeled Z-Eltrombopag. Z-Eltrombopag is an orally active thrombopoietin-receptor non-peptide agonist with platelet-stimulating activity for the study of chronic immune thrombocytopenia. Eltrombopag also has strong inhibitory effects on multidrug-resistant Staphylococcus aureus (Staphylococcus aureus) and can induce apoptosis (apoptosis) in liver cancer cells .
    Eltrombopag-13C4
  • HY-15306R
    Eltrombopag (Standard)

    SB-497115 (Standard)

    		 Reference Standards Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Standard) is the analytical standard of Eltrombopag. This product is intended for research and analytical applications. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag (Standard)
  • HY-15306AR
    Eltrombopag Olamine (Standard)

    Eltrombopag diethanolamine salt (Standard); SB-497115GR (Standard)

    		 Reference Standards Thrombopoietin Receptor Bacterial Apoptosis Infection Cardiovascular Disease Cancer
    Eltrombopag (Olamine) (Standard) is the analytical standard of Eltrombopag (Olamine). This product is intended for research and analytical applications. Eltrombopag Olamine (Eltrombopag diethanolamine salt) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag Olamine owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag Olamine can be used for the research of cardiovascular. Eltrombopag Olamine also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag Olamine can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag Olamine (Standard)
  • HY-125101A
    Rafutrombopag diolamine

    		Thrombopoietin Receptor Cardiovascular Disease
    Rafutrombopag diolamine is the derivative of Rafutrombopag. Rafutrombopag is a thrombopoietin receptor agonist .
    Rafutrombopag diolamine
  • HY-14756
    Totrombopag

    		Thrombopoietin Receptor Others
    Totrombopag is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag can be used to study platelet production and megakaryocyte biology .
    Totrombopag
  • HY-135041
    Totrombopag choline

    SB-559448 choline

    		 Thrombopoietin Receptor Others
    Totrombopag (SB-559448) choline is an orally effective thrombopoietin receptor (TpoR) agonist. By activating TpoR, Totrombopag choline initiates an intracellular signaling cascade mediated by JAK2 kinase and the transcription factor Stat5, a signaling process that is the primary mechanism regulating megakaryocyte growth and differentiation into platelets. Totrombopag choline can be used to study platelet production and megakaryocyte biology .
    Totrombopag choline
  • HY-W713365
    Eltrombopag-d3

    SB-497115-d3

    		 Isotope-Labeled Compounds Thrombopoietin Receptor Apoptosis Bacterial Infection Cardiovascular Disease Cancer
    Eltrombopag-d3 (SB-497115-d3) is deuterium labeled Eltrombopag. Eltrombopag (SB-497115) is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to research low blood platelet counts with chronic immune thrombocytopenia. Eltrombopag can be used for the research of cardiovascular. Eltrombopag also has highly inhibitory effects against multidrug resistant Staphylococcus aureus. Eltrombopag can induce apoptosis in hepatocellular carcinomab (HCC) as well .
    Eltrombopag-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: